Asset-centricity

Last updated

Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development. [1] [2] [3]

Contents

The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely held belief that it has become too expensive. [2] [4] It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital. [5]

A typical asset-centric startup company would have a single asset, or sometimes two, with a team of experts, including drug developers, shared across a back-end structure and across a variety of portfolio life sciences companies. These team members would coalesce for specific, focused drug-discovery projects [2] The bulk of funding would support the development of the primary asset, with the rest supporting a secondary asset and infrastructure. [1] [5] [6] [7]

History

The asset-centric model of investing was developed by Index Ventures, a venture capital firm. [7] [8] Forms of the asset-centric model have subsequently been adopted by other life sciences investment firms such as Atlas Venture and Symphony Capital. [2]

Examples of Asset-Centric companies

Examples of life sciences companies built on the asset-centric investing model include:

Related Research Articles

Corporate venture capital (CVC) is the investment of corporate funds directly in external startup companies. CVC is defined by the Business Dictionary as the "practice where a large firm takes an equity stake in a small but innovative or specialist firm, to which it may also provide management and marketing expertise; the objective is to gain a specific competitive advantage." Examples of CVCs include GV and Intel Capital.

Christoph Westphal is an American biomedical businessman.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

Kevin Johnson is a partner at medicxi, a venture capital firm focused on life sciences investments based on the asset-centric approach to investing. He was formerly with Index Ventures, having joined the venture capital firm in 2010.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

HealthCap is a specialized provider of venture capital within life sciences. HealthCap invests in innovative companies with focus on therapeutics. As of 2023, HealthCap has invested in over 125 companies since inception and completed initial public offerings of more than 45 companies. HealthCap has offices in Stockholm and Lausanne.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Abingworth LLP is a transatlantic bioscience investment firm founded in 1973 by a pair of London stockbrokers, Peter Dicks and Hon. Anthony Montagu. Abingworth had initially sought to extend its investments into the biotechnology industry in the late 1980s, and has subsequently been investing in life science and healthcare services companies since at least 2001, and had expanded to include information technology firm investments by 2016.

OvaScience was a publicly traded biotechnology company, focused on female infertility. It was founded in 2011 by Michelle Dipp, Richard Aldrich, Christoph Westphal, Jonathan Tilly, and David Sinclair based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. Tilly's work was controversial, with some groups unable to replicate it.

Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised four funds: Foresite Capital Fund I, II, III, IV and V.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

Emerald Cloud Lab (ECL) is a privately-owned biotech startup. The company focuses on advancing laboratory virtualization, for chemistry and biotechnology, by building the first fully functional cloud lab, allowing scientists to conduct all of their wet lab research without being in a physical laboratory.

H1 Inc. is an global healthcare data technology company founded in 2017, and headquartered in New York City. The company's database is used by healthcare and pharmaceutical companies and related organizations to identify healthcare professionals to partner with on research in order to accelerate development of drugs and other treatments. The company has over 400 employees worldwide and about 100 clients including pharmaceutical companies Novartis and AstraZeneca as of November 2021.

Versant Ventures ("Versant") is an American Venture capital firm headquartered in San Francisco, California. It is focused on making investments in the healthcare and biotechnology industries.

References

  1. 1 2 "Decentralising drug research". The Economist. May 24, 2014.
  2. 1 2 3 4 5 6 7 "Venture capitalists ride biotech wave one drug at a time". Reuters. April 10, 2015.
  3. ↑ "Atlas Venture unveils a $280M pure play biotech startup fund". FierceBiotech. April 17, 2015.
  4. ↑ "Why drugs are expensive: It's the science, stupid". Scientific American. January 6, 2014.
  5. 1 2 "The Lone Biotech Bear?". Forbes. January 21, 2015.
  6. ↑ "Glaxo Joins J&J in $200 Million Fund With Index Ventures". Bloomberg News. March 21, 2012.
  7. 1 2 "Index Ventures adds big pharma to asset-centric model". EPVantage. March 21, 2012.
  8. ↑ "Index Ventures appoints antibody expert as partner". MedNous. September 3, 2010.
  9. ↑ "Lilly buys back a migraine therapy from Arteaus Therapeutics". FierceBiotech. January 13, 2014.
  10. ↑ "Asset-Centric Milestone". BioCentury. January 20, 2014.
  11. ↑ "J&J stays mum about cash, but biotech buyout is a landmark win for Index fund". FierceBiotech. March 18, 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.